Luca Lipani
CEO & Co-Founder
Transdermal Diagnostics
Diabetes is a global health crisis, where 6.7 million people die prematurely each year. Worldwide, diabetes afflicts over 536 million people, of which ca. 50% are diagnosed; of those, around 10% are diagnosed as Type 1, and 90% as Type 2; furthermore, while there are an estimated 541 million individuals with pre-diabetes, only 15% have been diagnosed. Unfortunately, major drawbacks in commercial monitoring devices – e.g. pain, cost, skin disruption and irritation, needle phobia, inconvenience - cause diabetic patients to poorly control blood sugar, exponentially increasing the risk of developing life-threatening co-morbidities and reducing overall life expectancy. We address this challenge by offering the world’s first 100% needle-free, affordable and wearable continuous glucose monitor. Our innovation will improve patient compliance to diabetes management by removing the commonly encountered barriers to adherence.